Doctors often treat coronary artery disease with a procedure called angioplasty to widen clogged or narrowed arteries using a metal stent. But those stents have been problematic for some patients, leading to blood clots and even heart attacks. The FDA has just approved medical use of a dissolvable stent manufactured by Abbott Labs, and this story heralds that decision.
The Reuters story included some details the Associated Press version did not–namely, what the stent is made of, what kind of drug is coated onto it, and what the plans are for rolling it out to hospitals.
But its almost giddy approach to the FDA announcement belies the fact that long-term safety and efficacy data are not yet in hand. Put another way, no one yet knows if these dissolvable stents will make a practical difference in heart disease patient outcomes. The AP story makes that crucial information a centerpiece of the text and, we think, does its readers a greater service.
Coronary heart disease is responsible for about 370,000 deaths each year in the U.S., according to the National Heart, Lung, and Blood Institute. The use of stents to prop open occluded blood vessels is a popular treatment but one fraught with problems. If dissolvable stents can help solve these problems in ways superior to other treatment alternatives, they represent a real and important advance. Only time will tell–and this story didn’t make that clear enough.
A reader would be hard-pressed to determine the cost of this new stent. The only cost information provided sits in the last paragraph of the story, where it notes that the dissolvable stent will apparently cost more than Abbott Lab’s drug-coated metal stent, marketed under the name Xience. (See our review of the AP story to see how much more in-depth they covered costs.)
We’re not given any numbers, just this quick summary: “Data released in October concluded Absorb was comparable to Abbott’s own Xience drug-coated metal stent in safety and effectiveness but showed a higher risk of heart attacks and blood clots.”
That’s a confusing statement. Given that stents are presumably intended to prevent heart attacks, how can the two stents be “comparable” in effectiveness if there’s a higher risk with one compared to the other?
Also left unsaid is that any long-term benefits (and harms) are “prospective,” as no clinical study has lasted long enough to find them.
The story mentions that one clinical study found a higher risk of heart attacks and blood clots in participants, complications that Abbott Labs apparently blames not on the stent but on surgeons’ lack of experience in using it.
A weakness here, though, as noted in the “benefits” segment above, is that there apparently have been no clinical trials that have lasted long enough for the stents to dissolve (about three years) in order to assess harms. The story should make that clear to readers.
One study—presumably conducted by Abbott Labs—is referenced but not explained in enough detail to permit a reader to judge its quality. The lab’s new release provides a bit more detail, but a reader still would not know if the trial design included a control group, whether it was “blinded,” etc.
Permanent metal mesh stents have complications, so the search for an alternative makes sense.
Both scientists quoted in this story are connected in some way to Abbott Labs; one is a (presumably paid) adviser to the company while the other led the company’s clinical trial. They are clearly identified. A reader would likely infer, correctly, that development of the new device has been funded by the lab. But had the reporter sought out an independent source or two, the murky nature of long-term effects of the stent might have become more obvious.
The clinical trial summarized in the story compared the dissolvable stent with a metal stent coated with a drug to minimize future blood clots.
The story would have been stronger if it also had mentioned traditional metal stents (with no drug coating) and the use of drugs to manage heart disease.
The story notes that Abbott Labs plans to make the stent available to some 100 hospitals in the near future, in order to train surgeons in its use, before “ramping up sales.” This was information that we wished had been in the Associated Press story on the topic, which we also reviewed.
Novelty is established in the first paragraph of this story and appears to be an accurate statement about what’s “newsy” here.
Although the story seems to be reasonably independent of the two available press releases found in the course of this analysis, its positive assessment of the new stent is consistent with the tone of the Abbott Labs’ release.